TAK1-mediated Autophagy and Fatty Acid Oxidation Prevent Hepatosteatosis and Tumorigenesis
Overview
Authors
Affiliations
The MAP kinase kinase kinase TGFβ-activated kinase 1 (TAK1) is activated by TLRs, IL-1, TNF, and TGFβ and in turn activates IKK-NF-κB and JNK, which regulate cell survival, growth, tumorigenesis, and metabolism. TAK1 signaling also upregulates AMPK activity and autophagy. Here, we investigated TAK1-dependent regulation of autophagy, lipid metabolism, and tumorigenesis in the liver. Fasted mice with hepatocyte-specific deletion of Tak1 exhibited severe hepatosteatosis with increased mTORC1 activity and suppression of autophagy compared with their WT counterparts. TAK1-deficient hepatocytes exhibited suppressed AMPK activity and autophagy in response to starvation or metformin treatment; however, ectopic activation of AMPK restored autophagy in these cells. Peroxisome proliferator-activated receptor α (PPARα) target genes and β-oxidation, which regulate hepatic lipid degradation, were also suppressed in hepatocytes lacking TAK1. Due to suppression of autophagy and β-oxidation, a high-fat diet challenge aggravated steatohepatitis in mice with hepatocyte-specific deletion of Tak1. Notably, inhibition of mTORC1 restored autophagy and PPARα target gene expression in TAK1-deficient livers, indicating that TAK1 acts upstream of mTORC1. mTORC1 inhibition also suppressed spontaneous liver fibrosis and hepatocarcinogenesis in animals with hepatocyte-specific deletion of Tak1. These data indicate that TAK1 regulates hepatic lipid metabolism and tumorigenesis via the AMPK/mTORC1 axis, affecting both autophagy and PPARα activity.
Role of hepatocyte RIPK1 in maintaining liver homeostasis during metabolic challenges.
Zhang W, Liu H, Zhang D, Yi Y, Tao L, Zhu Y Elife. 2025; 13.
PMID: 39886919 PMC: 11785375. DOI: 10.7554/eLife.96798.
Banerjee A, Farci P Int J Mol Sci. 2024; 25(16).
PMID: 39201329 PMC: 11354981. DOI: 10.3390/ijms25168641.
Cheng Z, Chu H, Seki E, Lin R, Yang L Front Cell Dev Biol. 2024; 12:1431921.
PMID: 39071804 PMC: 11272544. DOI: 10.3389/fcell.2024.1431921.
USP13 ameliorates nonalcoholic fatty liver disease through inhibiting the activation of TAK1.
Tang M, Cao H, Ma Y, Yao S, Wei X, Tan Y J Transl Med. 2024; 22(1):671.
PMID: 39033101 PMC: 11264885. DOI: 10.1186/s12967-024-05465-4.
Zhao Y, Fan S, Zhu H, Zhao Q, Fang Z, Xu D Nat Commun. 2024; 15(1):5441.
PMID: 38937512 PMC: 11211476. DOI: 10.1038/s41467-024-49854-1.